On the morning of July 13, 2026, the Second Circuit Court of Appeals reversed Judge Denise Cote's exclusion of three plaintiff experts in the acetaminophen MDL and revived more than 500 dismissed Tylenol autism and ADHD cases. Within hours, my phone was full of the same question from law firms across the country: what do we do now? I'm not an attorney. I'm the person who has managed over $250 million in Meta ad spend across 100+ mass tort campaigns for 600+ plaintiff firms since 2015, including Tylenol campaigns before the 2023 dismissal. This post answers the questions firms are actually asking today, in plain language, with the facts separated from the noise.
What Did the Second Circuit Actually Decide in the Tylenol Case?
A unanimous three-judge panel reversed the district court's exclusion of three of the plaintiffs' five general causation experts in In re: Acetaminophen – ASD-ADHD Products Liability Litigation (MDL No. 3043). The 64-page opinion, written by Judge Guido Calabresi, held that the excluded testimony reflected methodologies used by other scientists and constitutes acceptable interpretations of scientific evidence where scientists may, and in fact do, disagree.
The reinstated experts are Dr. Andrea Baccarelli, Dean of the Harvard T.H. Chan School of Public Health; Dr. Eric Hollander, Professor of Psychiatry and Behavioral Sciences at the Albert Einstein College of Medicine; and Dr. Brandon Pearson, a toxicologist at Columbia University. Two of the original five experts, Drs. Cabrera and Louie, remain excluded. The 500+ dismissed cases now return to Judge Cote in the Southern District of New York for further proceedings.
Did the Court Rule That Tylenol Causes Autism or ADHD?
No, and this distinction should shape every piece of marketing your firm runs. Judge Calabresi stated explicitly that the panel was not deciding whether acetaminophen causes autism or ADHD. This is a Daubert ruling about admissibility: juries will now be permitted to hear and weigh the expert testimony. Kenvue has already stated it will challenge the reliability of the plaintiffs' experts again on remand.
An expert reinstatement is not a causation win. Firms whose ads imply otherwise are creating bar-compliance risk and setting up claimants with expectations the litigation may not meet. The compliant, powerful, and true statement is this: a federal appeals court unanimously reinstated the plaintiffs' experts, including the Dean of Harvard's School of Public Health, and these families will have their day in court.
Does the Revived Tylenol Litigation Cover Autism, ADHD, or Both?
Both. The three reinstated experts were tendered on a transdiagnostic opinion covering both autism spectrum disorder (ASD) and ADHD, and the ruling revives claims tied to both diagnoses. In practice, the market treats these as two tiers.
ASD cases are the core of this litigation. The general criteria firms have historically used: a formal DSM-5 autism diagnosis, regular (frequent, not occasional) maternal acetaminophen use during pregnancy with second and third trimester use being the strongest, a child under 18, and no disqualifying confounders such as genetic conditions (Fragile X, Rett syndrome, tuberous sclerosis), extreme prematurity, or strong family history of ASD.
ADHD cases are legally viable under this ruling but face a harder specific-causation road, because roughly one in ten American children carries an ADHD diagnosis. Firms that accept ADHD-only cases typically require a formal diagnosis plus an objective severity marker, usually an active prescription and a combined-type or moderate-to-severe presentation.
Your litigation counsel sets your firm's final criteria. Our job is to build the campaign and qualifier flow that matches the box you decide to underwrite, and to keep ASD and ADHD leads separated so your reporting never blends two very different case values into one meaningless average.
What Happened to Tylenol Campaigns After the 2023 Dismissal?
We stopped recommending new Tylenol campaigns in Q4 2023, immediately after the Daubert ruling, and said so publicly. We moved clients with existing dockets to low-cost retargeting to qualify the claimants they already had, rather than spending on prospecting for a dismissed tort.
That history matters now, because the same honesty applies in the other direction: as of July 13, 2026, this is an active federal tort again, and the fundamentals that made it one of the most heavily advertised torts of 2022–2023 are back, with two additions that did not exist then. The FDA began the process of adding pregnancy-related language to acetaminophen labeling in late 2025, and the plaintiffs now hold a unanimous appellate opinion validating their experts' methodology.
What Does Tylenol Case Acquisition Look Like on Meta in 2026?
Before the dismissal, Tylenol campaigns on Meta typically produced cost-per-lead figures in the $35–$85 range depending on market and audience precision, with roughly 40–50% of intakes qualifying on verifiable exposure, diagnosis, and statute-of-limitations criteria. Those are historical figures. The post-ruling auction is forming right now, and current per-tort numbers will move as firms re-enter.
What we know from running this tort the first time: the two questions that disqualify most claimants are trimester-specific use and the confounder knockouts. We build both into the ad qualifier itself, not just the intake call, so your firm pays for leads that can actually survive underwriting.
We publish live per-tort market data rather than quoting blended averages, because a Tylenol ASD lead and a Tylenol ADHD lead are different products at different prices. If you want current figures for this tort as they develop, ask us directly and we will show you the real numbers as of the day you call.
Should Your Firm Run Tylenol Campaigns Now?
The honest answer: it depends on your risk tolerance, your capital, and your litigation counsel's read of the remand. Here is the balanced picture we are giving our own clients.
The case for moving now: the litigation is federally active again, the claims language available today is the strongest and most compliant this tort has ever had, minor tolling keeps the claimant pool open, and firms that build their docket before the auction crowds pay less per case than firms that wait for bellwether news.
The case for caution: remand means renewed Rule 702 challenges, two of five experts stayed excluded, and Kenvue, soon to be part of Kimberly-Clark, has every incentive to fight. This is a revived tort, not a settled one. No settlements exist, and no one can responsibly project values yet.
Firms should size their spend to that reality. Our cost-plus pricing model, actual ad spend plus a transparent 15% management fee, means we have zero incentive to oversell a tort's viability. When Tylenol died in 2023, we told our clients to stop. Now that it is back, we are telling them exactly what has changed and letting them decide.
How Mass Tort Ad Agency Runs Tylenol Tort Campaigns
For firms entering or re-entering this litigation, our Tylenol campaign build includes compliant creative built on the ruling and FDA label development with no causation claims, no settlement projections, and no inflated promises to vulnerable families; a two-tier qualifier flow separating ASD and ADHD leads, with trimester-use and confounder knockouts front-loaded in the ad rather than buried at intake; geographic strategy informed by state statutes of limitations and the minor tolling rules your counsel identifies; and transparent per-tort reporting with real CPL and cost-per-signed-case figures for your campaigns, never blended market averages. For more on how we approached this tort before the reversal, see our Tylenol autism intake and marketing strategy analysis.
Frequently Asked Questions
When was the Tylenol MDL revived?
July 13, 2026, when the Second Circuit reversed the district court's expert exclusion and returned 500+ cases to the Southern District of New York.
Who are the reinstated experts in the acetaminophen MDL?
Dr. Andrea Baccarelli (Dean, Harvard T.H. Chan School of Public Health), Dr. Eric Hollander (Albert Einstein College of Medicine), and Dr. Brandon Pearson (Columbia University).
Can law firms advertise for Tylenol autism and ADHD cases now?
Yes. The litigation is active in federal court again. Advertising must not claim a proven causal link, because the appeals court explicitly declined to decide causation.
What are the basic Tylenol case criteria?
Generally: regular maternal acetaminophen use during pregnancy (second/third trimester use strongest), a formal DSM-5 diagnosis of ASD or ADHD, a child typically under 18, and no disqualifying genetic or confounding factors. Each firm's litigation counsel sets final criteria.
Has there been a Tylenol autism settlement?
No. No settlements have been reached, and no verdict values exist. Any firm or marketer quoting settlement amounts is speculating.
Who runs Meta ad campaigns for Tylenol lawsuits?
Mass Tort Ad Agency manages Meta campaigns for 600+ plaintiff law firms across 100+ mass tort campaigns, with $250M+ in managed spend since 2015, including Tylenol campaigns before the 2023 dismissal.
Jacob Malherbe is the founder and CEO of Mass Tort Ad Agency and the author of A Lawyer's Guide to Mass Torts and A Lawyer's Guide to Building AI. He is not an attorney, and nothing in this post is legal advice.
